Company Analysis

Oncolytics Biotech, Inc. (ONCY)

Nasdaq: ONCY · Pharmaceutical Preparations · Calgary · filing with the SEC since 2002
Grade4.8
◀ Past 2.3● Present 6.4▶ Future 5.0
7 est.

Who owns Oncolytics Biotech, Inc.

As filed with the SEC
Holders of 5% or more
1
Anson Funds Management LP holds 7% of Common Stock, no par value, as its SCHEDULE 13G/A filed Nov 14, 2025 says.
Directors and officers
14
report now, of 14 people on the record since 2026. Their holdings as a group are not read here.
Institutions as a whole
n/a
The record does not read the share held by managers that file Form 13F, so none is printed and no split of the rest is estimated. What it holds is the 1 named at left.
Holders of 5% or moreshare of the class, as filed
Anson Funds Management LP
SCHEDULE 13G/A · filed Nov 14, 2025 · Common Stock, no par value · 9.6% in Feb 14, 2025
7%
What ONCY reports owning in othersstakes of 5% or more, and other ties

3 subsidiaries in 3 countries, from the list filed with the 10-K filed Mar 30, 2026.

Insider tradesForm 4
0sales
14purchases
0sales on a scheduled plan
0people selling
$0sold, in dollars
$400,000bought, in dollars
Open-market trades on Form 4 from Sep 30, 2025 to Sep 30, 2026. A scheduled plan is a selling program set in advance under SEC rule 10b5-1. The trades are listed as filed and do not feed the grade.
By calendar yearSoldBought
26
2026 runs to Sep 30, 2026. Dollars as filed, summed by the transaction date.
People who traded in the window10 of 14 on the roster
PersonRole as filedSalesSoldOn a planBuysBought
Kelly JaredChief Executive Officer0$003$0
Seizinger Bernd R.director0$003$200,000
Look KirkChief Financial Officer0$001$0
Aromando AndrewChief Business Officer0$001$0
Hagerman AllisonChief Technology Officer0$001$0
Heineman Thomas CharlesChief Medical Officer0$001$0
Andrews Patricia Sdirector0$001$0
Brown Deborah Margaretdirector0$001$0
Parsons James T.director0$001$0
Pisano Waynedirector0$001$0
SI Assistanton ONCY · research, not advice